98. 好酸球性消化管疾患 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AK002
Allakos Inc.
2020 Phase 2;Phase 3 EUCTR2019-004391-19-NL Australia;Netherlands;United States;
Allakos, Inc.
2021 Phase 3 NCT04856891 United States;
2018 Phase 2 NCT03664960 United States;
2018 Phase 2 NCT03496571 United States;
APD334
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
APT-1011
Adare Pharmaceutical
2017 Phase 2 EUCTR2016-004749-10-ES Belgium;Canada;Germany;Spain;United States;
2017 Phase 2 EUCTR2016-004749-10-DE Belgium;Canada;Germany;Spain;Switzerland;United States;
2017 Phase 2 EUCTR2016-004749-10-BE Belgium;Canada;Germany;Spain;Switzerland;United States;
Adare Pharmaceuticals, Inc.
2017 Phase 2 NCT03191864 Belgium;Canada;Germany;Spain;Switzerland;United States;
Ellodi Pharmaceuticals, LP
2021 Phase 3 NCT05083312 Australia;United States;
2020 Phase 3 NCT04281108 Australia;Germany;Spain;United States;
APT-1011 -
Adare Pharmaceuticals US, LP
2020 Phase 3 EUCTR2019-001521-27-ES Australia;Germany;Spain;Switzerland;United States;
2020 Phase 3 EUCTR2019-001521-27-DE Australia;Germany;Spain;United States;
AR401959 L-arginine
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Allergy immunotherapy (allergy shots)
United States Naval Medical Center, San Diego
2012 - NCT01685034 -
BT-11
Landos Biopharma Inc.
2022 Phase 1 NCT04835168 -
BUET
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Dr. Falk Pharma GmbH
2017 Phase 3 EUCTR2014-001485-99-DK Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-NL Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-BE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 - EUCTR2014-001485-99-ES Spain;Switzerland;
2015 Phase 3 EUCTR2014-001485-99-GB Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001485-99-DE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001484-12-NL Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-ES Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-DE Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-BE Belgium;Germany;Netherlands;Spain;Switzerland;
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
BUL
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
BUU 0.4mg/ml
Dr. Falk Pharma GmbH
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
Barium
Mayo Clinic
2017 - NCT03290482 United States;
2013 - NCT01865825 United States;
Beclomethasone dipropionate
Penn State University
2010 Phase 1 NCT01016223 United States;
Benralizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-002871-32-IT Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca
2022 Phase 3 NCT05251909 Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United States;Vietnam;
2020 Phase 3 NCT04543409 Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-GB Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-FR Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-ES Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-002871-32-PL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Hibi Kazushige
2022 Phase 3 JPRN-jRCT2031210500 America;Australia;Brazil;Canada;China;France;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;Vietnam;
2020 Phase 3 JPRN-jRCT2061200026 Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russia;Spain;UK;US;
Bethanechol
University of Iowa
2014 Phase 2 NCT02058537 United States;
Budesonide
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
2019 Phase 2 EUCTR2019-002691-14-IT Italy;
Mayo Clinic
2008 Phase 2/Phase 3 NCT00728481 United States;
Shire
2009 Phase 2 NCT00762073 United States;
Swiss EE Study Group
2005 Phase 2 NCT00271349 Switzerland;
Budesonide 0.5 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Budesonide 0.5 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Budesonide 0.5mg orodispersible tablet twice daily
Dr. Falk Pharma GmbH
2016 Phase 3 NCT02493335 Germany;
Budesonide 1 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets (BUL 1 mg)
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide 1mg orodispersible tablet twice daily
Dr. Falk Pharma GmbH
2016 Phase 3 NCT02493335 Germany;
2015 Phase 3 NCT02434029 Germany;
Budesonide 2 mg orodispersible tablets (BUL 2 mg)
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-PT Austria;Germany;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide [0.4mg/ml] viscous suspension
Dr. Falk Pharma GmbH
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
Budesonide oral suspension
Shire
2017 Phase 3 NCT03245840 United States;
Budesonide oral suspension [0.2 mg/ml]
Dr. Falk Pharma GmbH
2020 Phase 2;Phase 3 EUCTR2017-003737-29-NL Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-PT Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-GR Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-GB Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-ES Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
- Phase 2;Phase 3 EUCTR2017-003737-29-DE Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
Budesonide plus Prevacid
Ranjan Dohil
2008 Phase 2 NCT00638456 United States;
CALY-002
Calypso Biotech BV
2020 Phase 1 NCT04593251 Belgium;Germany;Netherlands;
CC
Hatano Ben
2021 Phase 3 JPRN-jRCT2051200140 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;UK;United States of America;
Zhang Changliang
2022 Phase 3 JPRN-jRCT2031210574 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States of America;
2022 Phase 3 JPRN-jRCT2021210067 Japan;
CC-93538
CELGENE INTERNATIONAL II SàRL
2022 Phase 3 EUCTR2020-004335-24-IT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-IT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Celgene
2021 Phase 3 NCT04991935 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT04753697 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
Celgene International II Sàrl
2022 Phase 3 EUCTR2020-004336-16-ES Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-PT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-DE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PL Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-DE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-BE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-AT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-BE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-AT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Cendakimab
CELGENE INTERNATIONAL II SàRL
2022 Phase 3 EUCTR2020-004335-24-IT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-IT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Celgene International II Sàrl
2022 Phase 3 EUCTR2020-004336-16-ES Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-PT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-DE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PL Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-DE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-BE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-AT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-BE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-AT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Citalopram
Amsterdam UMC
2021 Phase 4 EUCTR2021-002288-24-NL Netherlands;
Compressa effervescente 0,5 mg di budesonide per uso orodispersibile
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Compressa effervescente 1 mg di budesonide per uso orodispersibile
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Cortisol
University of Colorado, Denver
2022 - NCT05246085 -
Dexlansoprazole
Mayo Clinic
2012 Phase 1/Phase 2 NCT01479231 United States;
Dupilumab
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
Regeneron Pharmaceuticals
2021 - NCT04776694 -
2020 Phase 3 NCT04394351 Canada;United States;
2018 Phase 3 NCT03633617 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 2 NCT02379052 United States;
Dupilumab (blinded)
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT03678545 United States;
Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT03678545 United States;
Dupixent
Regeneron Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-000844-25-SE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-PT Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-NL Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-IT Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-GB Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-FR Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-ES Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-DE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-BE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
E0E food introduction-2nd
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
ESO-101
EsoCap AG
2021 Phase 2 NCT04849390 Germany;Netherlands;Spain;Switzerland;
2021 Phase 2 EUCTR2020-000082-16-DE Germany;Netherlands;Spain;Switzerland;
2020 Phase 2 EUCTR2020-000082-16-NL Germany;Netherlands;Spain;Switzerland;
EUR-1100
Aptalis Pharma
2011 Phase 1/Phase 2 NCT01386112 United States;
Forest Laboratories
2012 - NCT01498497 United States;
EoE Food introduction-3rd dose
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
EoE food introduction-1st
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
Esomeprazole
Mayo Clinic
2008 Phase 2/Phase 3 NCT00728481 United States;
University of Utah
2004 Phase 2 NCT00123656 United States;
Walter Reed Army Medical Center
2008 - NCT00895817 United States;
EsophaCap
Mayo Clinic
2017 - NCT03290482 United States;
Esophageal dilation
Vanderbilt University
2008 - NCT00880906 United States;
Esophagogastroduodenoscopy
University of Utah
2016 Early Phase 1 NCT04069429 United States;
Etrasimod
Arena Pharmaceuticals
2021 Phase 2 NCT04682639 Australia;Belgium;Netherlands;Spain;Switzerland;United States;
Etrasimod L-arginine
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Famotidine
Mayo Clinic
2020 Phase 2 NCT04248712 United States;
Fasenra
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Florence 30 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Florence 60 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Florence 90 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Flovent
Marc Rothenberg, MD
2007 Phase 2 NCT00426283 United States;
Fluticasone
Azienda Policlinico Umberto I
2012 Phase 4 NCT01846962 Italy;
Claire Daniels
2018 Phase 4 NCT03781596 United States;
Mayo Clinic
2005 Phase 2 NCT00275561 United States;
Medical College of Wisconsin
2012 Phase 3 NCT01702701 United States;
Technische Universität München
2011 - NCT01624129 Germany;
University of Utah
2004 Phase 2 NCT00123656 United States;
Fluticasone MDI
University of North Carolina, Chapel Hill
2015 Phase 4 NCT02019758 United States;
Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Children's Hospital Medical Center, Cincinnati
2016 Phase 2/Phase 3 NCT02610816 United States;
Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Children's Hospital Medical Center, Cincinnati
2016 Phase 2/Phase 3 NCT02778867 United States;
Fluticasone Propionate, USP
Adare Pharmaceuticals US, LP
2020 Phase 3 EUCTR2019-001521-27-ES Australia;Germany;Spain;Switzerland;United States;
2020 Phase 3 EUCTR2019-001521-27-DE Australia;Germany;Spain;United States;
Gold
Endoscopy Center, Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University.
2016 - ChiCTR-DOD-16009003 China;
High dose budesonide suspension
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
High dose budesonide tablet
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
Honey
Walter Reed National Military Medical Center
2014 - NCT02125851 United States;
IRL201104
Revolo Biotherapeutics
2021 Phase 2 NCT05084963 United States;
Infliximab
Swiss EE Study Group
2007 Phase 2 NCT00523354 Switzerland;
Inhaled/swallowed budesonide
University of North Carolina, Chapel Hill
2009 - NCT00961233 United States;
Intraluminal Impedance
Mayo Clinic
2015 Early Phase 1 NCT02353078 United States;
Intubated with Propofol (IP)
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
Intubated with Sevoflurane (IS)
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
Jorveza
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Jorveza 0.5 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Jorveza 0.5 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Jorveza 1 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Jorveza 1 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-PT Austria;Germany;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Lirentelimab
Allakos, Inc.
2020 Phase 3 NCT04620811 United States;
Lirentelimab (AK002)
Allakos, Inc.
2020 Phase 3 NCT04322604 United States;
2020 Phase 2/Phase 3 NCT04322708 Australia;Netherlands;United States;
Loratadine
Mayo Clinic
2020 Phase 2 NCT04248712 United States;
Losartan Potassium
Children's Hospital Medical Center, Cincinnati
2017 Phase 2 NCT03029091 United States;
2013 Phase 2 NCT01808196 United States;
Low dose budesonide tablet
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
MEDI-563
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-002871-32-IT Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-GB Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-FR Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-ES Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-002871-32-PL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Mepolizumab
Children's Hospital Medical Center, Cincinnati
2001 Phase 1/Phase 2 NCT00266565 United States;
GlaxoSmithKline
2006 Phase 2 NCT00358449 Australia;Canada;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd.
2006 Phase 2 EUCTR2005-006074-10-GB United Kingdom;
University of North Carolina, Chapel Hill
2019 Phase 2 NCT03656380 United States;
Mometasone furoate
Mogens Bove
2014 Phase 2 NCT02113267 Sweden;
Montelukast
Children's Mercy Hospital Kansas City
2011 - NCT01458418 United States;
2005 - NCT00148603 United States;
Medical College of Wisconsin
2012 Phase 3 NCT01702701 United States;
Montelukast/ Singulair
Mayo Clinic
2007 Phase 1 NCT00511316 United States;
NIOX MINO® Airway Inflammation Monitor
Tufts Medical Center
2010 - NCT01170234 United States;
Nasonex
NU-sjukvården, Norra Älvsborgs Länssjukhus
2013 Phase 2 EUCTR2012-005842-39-SE Sweden;
Nitric Oxide
Mayo Clinic
2013 - NCT01929824 United States;
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
University of North Carolina, Chapel Hill
2016 - NCT02722148 United States;
OC000459
Oxagen Ltd
2010 Phase 2 NCT01056783 Switzerland;
Omalizumab
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 2 NCT00084097 United States;
O & O Alpan LLC
2009 Phase 1 NCT01040598 United States;
University of Utah
2005 Phase 2 NCT00123630 United States;
Omeprazole
Claire Daniels
2018 Phase 4 NCT03781596 United States;
Omeprazole 20 MG Oral Tablet
Wroclaw Medical University
2017 - NCT04803162 Poland;
Omeprazole 20mg BID
University of Colorado, Denver
2020 Phase 4 NCT04149470 United States;
Oral Budesonide
Baylor College of Medicine
2013 Phase 2 NCT01821898 United States;
Oral Budesonide Suspension (MB-9)
Shire
2012 Phase 2 NCT01642212 United States;
Oral Budesonide Suspension (OBS)
Shire
2016 Phase 3 NCT02736409 United Kingdom;United States;
2015 Phase 3 NCT02605837 United States;
Oral Viscous Budesonide
University of North Carolina, Chapel Hill
2015 Phase 4 NCT02019758 United States;
Oral Viscous Budesonide (OVB)
Azienda Policlinico Umberto I
2012 Phase 4 NCT01846962 Italy;
Oral cromolyn sodium
University of Tennessee
2014 Phase 4 NCT02371941 United States;
QAX576
Novartis Pharmaceuticals
2009 Phase 2 NCT01022970 United States;
RPC4046
Celgene
2014 Phase 2 NCT02098473 Canada;Switzerland;United States;
Reslizumab
Ception Therapeutics
2008 Phase 3 NCT00635089 Canada;United States;
2008 Phase 2/Phase 3 NCT00538434 Canada;United States;
SB-240563
GlaxoSmithKline Research & Development Ltd.
2006 Phase 2 EUCTR2005-006074-10-GB United Kingdom;
SCH55700
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 2 NCT00017862 United States;
Sirolimus
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 1 NCT01814059 United States;
Steroid and Proton Pump Inhibitor Therapy
Vanderbilt University
2008 - NCT00880906 United States;
Sucralfate
Mayo Clinic
2015 Early Phase 1 NCT02353078 United States;
Swallowed fluticasone
Walter Reed Army Medical Center
2008 - NCT00895817 United States;
Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
Dallas VA Medical Center
2007 Phase 4 NCT01404832 United States;
Viaskin Milk 500 mcg
Children's Hospital of Philadelphia
2015 Phase 2 NCT02579876 United States;
Viscous/swallowed budesonide
University of North Carolina, Chapel Hill
2009 - NCT00961233 United States;
Vitamin D
Arkansas Children's Hospital Research Institute
2019 - NCT03615950 United States;
Vonoprazan
Second department of Internal Medicine, Shimane University Faculty of Medicine
2016 - JPRN-UMIN000021041 Japan;
Wheat
Mayo Clinic
2015 - NCT02434705 United States;
Xanthan gum
Walter Reed National Military Medical Center
2014 - NCT02125851 United States;
Xylose
Mayo Clinic
2014 - NCT02314455 United States;
Zofran - no intubation
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
budesonide effervescent tablet for orodispersible use
Dr. Falk Pharma GmbH
2017 Phase 3 EUCTR2014-001485-99-DK Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-NL Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-BE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 - EUCTR2014-001485-99-ES Spain;Switzerland;
2015 Phase 3 EUCTR2014-001485-99-GB Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001485-99-DE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001484-12-NL Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-ES Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-DE Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-BE Belgium;Germany;Netherlands;Spain;Switzerland;
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
Allakos Inc.
2020 Phase 2;Phase 3 EUCTR2019-004391-19-NL Australia;Netherlands;United States;
Allakos, Inc.
2021 Phase 3 NCT04856891 United States;
2018 Phase 2 NCT03664960 United States;
2018 Phase 2 NCT03496571 United States;
APD334
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
APT-1011
Adare Pharmaceutical
2017 Phase 2 EUCTR2016-004749-10-ES Belgium;Canada;Germany;Spain;United States;
2017 Phase 2 EUCTR2016-004749-10-DE Belgium;Canada;Germany;Spain;Switzerland;United States;
2017 Phase 2 EUCTR2016-004749-10-BE Belgium;Canada;Germany;Spain;Switzerland;United States;
Adare Pharmaceuticals, Inc.
2017 Phase 2 NCT03191864 Belgium;Canada;Germany;Spain;Switzerland;United States;
Ellodi Pharmaceuticals, LP
2021 Phase 3 NCT05083312 Australia;United States;
2020 Phase 3 NCT04281108 Australia;Germany;Spain;United States;
APT-1011 -
Adare Pharmaceuticals US, LP
2020 Phase 3 EUCTR2019-001521-27-ES Australia;Germany;Spain;Switzerland;United States;
2020 Phase 3 EUCTR2019-001521-27-DE Australia;Germany;Spain;United States;
AR401959 L-arginine
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Allergy immunotherapy (allergy shots)
United States Naval Medical Center, San Diego
2012 - NCT01685034 -
BT-11
Landos Biopharma Inc.
2022 Phase 1 NCT04835168 -
BUET
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Dr. Falk Pharma GmbH
2017 Phase 3 EUCTR2014-001485-99-DK Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-NL Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-BE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 - EUCTR2014-001485-99-ES Spain;Switzerland;
2015 Phase 3 EUCTR2014-001485-99-GB Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001485-99-DE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001484-12-NL Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-ES Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-DE Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-BE Belgium;Germany;Netherlands;Spain;Switzerland;
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
BUL
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
BUU 0.4mg/ml
Dr. Falk Pharma GmbH
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
Barium
Mayo Clinic
2017 - NCT03290482 United States;
2013 - NCT01865825 United States;
Beclomethasone dipropionate
Penn State University
2010 Phase 1 NCT01016223 United States;
Benralizumab
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-002871-32-IT Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca
2022 Phase 3 NCT05251909 Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United States;Vietnam;
2020 Phase 3 NCT04543409 Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-GB Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-FR Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-ES Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-002871-32-PL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Hibi Kazushige
2022 Phase 3 JPRN-jRCT2031210500 America;Australia;Brazil;Canada;China;France;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;Vietnam;
2020 Phase 3 JPRN-jRCT2061200026 Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russia;Spain;UK;US;
Bethanechol
University of Iowa
2014 Phase 2 NCT02058537 United States;
Budesonide
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
2019 Phase 2 EUCTR2019-002691-14-IT Italy;
Mayo Clinic
2008 Phase 2/Phase 3 NCT00728481 United States;
Shire
2009 Phase 2 NCT00762073 United States;
Swiss EE Study Group
2005 Phase 2 NCT00271349 Switzerland;
Budesonide 0.5 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Budesonide 0.5 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Budesonide 0.5mg orodispersible tablet twice daily
Dr. Falk Pharma GmbH
2016 Phase 3 NCT02493335 Germany;
Budesonide 1 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Budesonide 1 mg orodispersible tablets (BUL 1 mg)
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide 1mg orodispersible tablet twice daily
Dr. Falk Pharma GmbH
2016 Phase 3 NCT02493335 Germany;
2015 Phase 3 NCT02434029 Germany;
Budesonide 2 mg orodispersible tablets (BUL 2 mg)
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-PT Austria;Germany;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Budesonide [0.4mg/ml] viscous suspension
Dr. Falk Pharma GmbH
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;
Budesonide oral suspension
Shire
2017 Phase 3 NCT03245840 United States;
Budesonide oral suspension [0.2 mg/ml]
Dr. Falk Pharma GmbH
2020 Phase 2;Phase 3 EUCTR2017-003737-29-NL Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-PT Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-GR Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-GB Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
2019 Phase 2;Phase 3 EUCTR2017-003737-29-ES Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
- Phase 2;Phase 3 EUCTR2017-003737-29-DE Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom;
Budesonide plus Prevacid
Ranjan Dohil
2008 Phase 2 NCT00638456 United States;
CALY-002
Calypso Biotech BV
2020 Phase 1 NCT04593251 Belgium;Germany;Netherlands;
CC
Hatano Ben
2021 Phase 3 JPRN-jRCT2051200140 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;UK;United States of America;
Zhang Changliang
2022 Phase 3 JPRN-jRCT2031210574 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States of America;
2022 Phase 3 JPRN-jRCT2021210067 Japan;
CC-93538
CELGENE INTERNATIONAL II SàRL
2022 Phase 3 EUCTR2020-004335-24-IT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-IT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Celgene
2021 Phase 3 NCT04991935 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 NCT04753697 Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
Celgene International II Sàrl
2022 Phase 3 EUCTR2020-004336-16-ES Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-PT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-DE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PL Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-DE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-BE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-AT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-BE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-AT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Cendakimab
CELGENE INTERNATIONAL II SàRL
2022 Phase 3 EUCTR2020-004335-24-IT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-IT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Celgene International II Sàrl
2022 Phase 3 EUCTR2020-004336-16-ES Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-PT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2022 Phase 3 EUCTR2020-004335-24-DE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-PL Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004336-16-DE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-BE Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004336-16-AT Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-BE Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004335-24-AT Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Citalopram
Amsterdam UMC
2021 Phase 4 EUCTR2021-002288-24-NL Netherlands;
Compressa effervescente 0,5 mg di budesonide per uso orodispersibile
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Compressa effervescente 1 mg di budesonide per uso orodispersibile
DR. FALK PHARMA GMBH
2017 Phase 3 EUCTR2014-001485-99-IT Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Cortisol
University of Colorado, Denver
2022 - NCT05246085 -
Dexlansoprazole
Mayo Clinic
2012 Phase 1/Phase 2 NCT01479231 United States;
Dupilumab
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
Regeneron Pharmaceuticals
2021 - NCT04776694 -
2020 Phase 3 NCT04394351 Canada;United States;
2018 Phase 3 NCT03633617 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2015 Phase 2 NCT02379052 United States;
Dupilumab (blinded)
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT03678545 United States;
Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati
2021 Phase 2 NCT03678545 United States;
Dupixent
Regeneron Pharmaceuticals, Inc.
2019 Phase 3 EUCTR2018-000844-25-SE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-PT Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-NL Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-IT Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-GB Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-FR Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-ES Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-DE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-000844-25-BE Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
E0E food introduction-2nd
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
ESO-101
EsoCap AG
2021 Phase 2 NCT04849390 Germany;Netherlands;Spain;Switzerland;
2021 Phase 2 EUCTR2020-000082-16-DE Germany;Netherlands;Spain;Switzerland;
2020 Phase 2 EUCTR2020-000082-16-NL Germany;Netherlands;Spain;Switzerland;
EUR-1100
Aptalis Pharma
2011 Phase 1/Phase 2 NCT01386112 United States;
Forest Laboratories
2012 - NCT01498497 United States;
EoE Food introduction-3rd dose
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
EoE food introduction-1st
Children's Hospital of Philadelphia
2022 Phase 4 NCT05247866 United States;
Esomeprazole
Mayo Clinic
2008 Phase 2/Phase 3 NCT00728481 United States;
University of Utah
2004 Phase 2 NCT00123656 United States;
Walter Reed Army Medical Center
2008 - NCT00895817 United States;
EsophaCap
Mayo Clinic
2017 - NCT03290482 United States;
Esophageal dilation
Vanderbilt University
2008 - NCT00880906 United States;
Esophagogastroduodenoscopy
University of Utah
2016 Early Phase 1 NCT04069429 United States;
Etrasimod
Arena Pharmaceuticals
2021 Phase 2 NCT04682639 Australia;Belgium;Netherlands;Spain;Switzerland;United States;
Etrasimod L-arginine
Arena Pharmaceuticals Inc.
2021 Phase 2 EUCTR2020-003226-23-NL Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-DE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
2021 Phase 2 EUCTR2020-003226-23-BE Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States;
Famotidine
Mayo Clinic
2020 Phase 2 NCT04248712 United States;
Fasenra
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Florence 30 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Florence 60 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Florence 90 µg/mL
EMS
2021 Phase 2 NCT02873468 -
Flovent
Marc Rothenberg, MD
2007 Phase 2 NCT00426283 United States;
Fluticasone
Azienda Policlinico Umberto I
2012 Phase 4 NCT01846962 Italy;
Claire Daniels
2018 Phase 4 NCT03781596 United States;
Mayo Clinic
2005 Phase 2 NCT00275561 United States;
Medical College of Wisconsin
2012 Phase 3 NCT01702701 United States;
Technische Universität München
2011 - NCT01624129 Germany;
University of Utah
2004 Phase 2 NCT00123656 United States;
Fluticasone MDI
University of North Carolina, Chapel Hill
2015 Phase 4 NCT02019758 United States;
Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Children's Hospital Medical Center, Cincinnati
2016 Phase 2/Phase 3 NCT02610816 United States;
Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Children's Hospital Medical Center, Cincinnati
2016 Phase 2/Phase 3 NCT02778867 United States;
Fluticasone Propionate, USP
Adare Pharmaceuticals US, LP
2020 Phase 3 EUCTR2019-001521-27-ES Australia;Germany;Spain;Switzerland;United States;
2020 Phase 3 EUCTR2019-001521-27-DE Australia;Germany;Spain;United States;
Gold
Endoscopy Center, Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University.
2016 - ChiCTR-DOD-16009003 China;
High dose budesonide suspension
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
High dose budesonide tablet
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
Honey
Walter Reed National Military Medical Center
2014 - NCT02125851 United States;
IRL201104
Revolo Biotherapeutics
2021 Phase 2 NCT05084963 United States;
Infliximab
Swiss EE Study Group
2007 Phase 2 NCT00523354 Switzerland;
Inhaled/swallowed budesonide
University of North Carolina, Chapel Hill
2009 - NCT00961233 United States;
Intraluminal Impedance
Mayo Clinic
2015 Early Phase 1 NCT02353078 United States;
Intubated with Propofol (IP)
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
Intubated with Sevoflurane (IS)
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
Jorveza
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-DE Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
2021 Phase 3 EUCTR2020-001314-37-AT Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland;
Jorveza 0.5 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Jorveza 0.5 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Jorveza 1 mg compresse orodispersibili
DR. FALK PHARMA GMBH
2021 Phase 3 EUCTR2017-003516-39-IT Germany;Italy;Spain;Switzerland;
Jorveza 1 mg orodispersible tablets
Dr. Falk Pharma GmbH
2021 Phase 3 EUCTR2020-001314-37-PT Austria;Germany;Portugal;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-ES Germany;Italy;Spain;Switzerland;
2021 Phase 3 EUCTR2017-003516-39-DE Germany;Italy;Spain;Switzerland;
Lirentelimab
Allakos, Inc.
2020 Phase 3 NCT04620811 United States;
Lirentelimab (AK002)
Allakos, Inc.
2020 Phase 3 NCT04322604 United States;
2020 Phase 2/Phase 3 NCT04322708 Australia;Netherlands;United States;
Loratadine
Mayo Clinic
2020 Phase 2 NCT04248712 United States;
Losartan Potassium
Children's Hospital Medical Center, Cincinnati
2017 Phase 2 NCT03029091 United States;
2013 Phase 2 NCT01808196 United States;
Low dose budesonide tablet
Dr. Falk Pharma GmbH
2011 Phase 2 NCT02280616 Germany;
MEDI-563
ASTRAZENECA AB
2020 Phase 3 EUCTR2019-002871-32-IT Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
AstraZeneca AB
2020 Phase 3 EUCTR2019-002871-32-NL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-GB Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-FR Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-ES Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002871-32-DE Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 3 EUCTR2019-002871-32-PL Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Mepolizumab
Children's Hospital Medical Center, Cincinnati
2001 Phase 1/Phase 2 NCT00266565 United States;
GlaxoSmithKline
2006 Phase 2 NCT00358449 Australia;Canada;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd.
2006 Phase 2 EUCTR2005-006074-10-GB United Kingdom;
University of North Carolina, Chapel Hill
2019 Phase 2 NCT03656380 United States;
Mometasone furoate
Mogens Bove
2014 Phase 2 NCT02113267 Sweden;
Montelukast
Children's Mercy Hospital Kansas City
2011 - NCT01458418 United States;
2005 - NCT00148603 United States;
Medical College of Wisconsin
2012 Phase 3 NCT01702701 United States;
Montelukast/ Singulair
Mayo Clinic
2007 Phase 1 NCT00511316 United States;
NIOX MINO® Airway Inflammation Monitor
Tufts Medical Center
2010 - NCT01170234 United States;
Nasonex
NU-sjukvården, Norra Älvsborgs Länssjukhus
2013 Phase 2 EUCTR2012-005842-39-SE Sweden;
Nitric Oxide
Mayo Clinic
2013 - NCT01929824 United States;
Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
University of North Carolina, Chapel Hill
2016 - NCT02722148 United States;
OC000459
Oxagen Ltd
2010 Phase 2 NCT01056783 Switzerland;
Omalizumab
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 2 NCT00084097 United States;
O & O Alpan LLC
2009 Phase 1 NCT01040598 United States;
University of Utah
2005 Phase 2 NCT00123630 United States;
Omeprazole
Claire Daniels
2018 Phase 4 NCT03781596 United States;
Omeprazole 20 MG Oral Tablet
Wroclaw Medical University
2017 - NCT04803162 Poland;
Omeprazole 20mg BID
University of Colorado, Denver
2020 Phase 4 NCT04149470 United States;
Oral Budesonide
Baylor College of Medicine
2013 Phase 2 NCT01821898 United States;
Oral Budesonide Suspension (MB-9)
Shire
2012 Phase 2 NCT01642212 United States;
Oral Budesonide Suspension (OBS)
Shire
2016 Phase 3 NCT02736409 United Kingdom;United States;
2015 Phase 3 NCT02605837 United States;
Oral Viscous Budesonide
University of North Carolina, Chapel Hill
2015 Phase 4 NCT02019758 United States;
Oral Viscous Budesonide (OVB)
Azienda Policlinico Umberto I
2012 Phase 4 NCT01846962 Italy;
Oral cromolyn sodium
University of Tennessee
2014 Phase 4 NCT02371941 United States;
QAX576
Novartis Pharmaceuticals
2009 Phase 2 NCT01022970 United States;
RPC4046
Celgene
2014 Phase 2 NCT02098473 Canada;Switzerland;United States;
Reslizumab
Ception Therapeutics
2008 Phase 3 NCT00635089 Canada;United States;
2008 Phase 2/Phase 3 NCT00538434 Canada;United States;
SB-240563
GlaxoSmithKline Research & Development Ltd.
2006 Phase 2 EUCTR2005-006074-10-GB United Kingdom;
SCH55700
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 2 NCT00017862 United States;
Sirolimus
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 1 NCT01814059 United States;
Steroid and Proton Pump Inhibitor Therapy
Vanderbilt University
2008 - NCT00880906 United States;
Sucralfate
Mayo Clinic
2015 Early Phase 1 NCT02353078 United States;
Swallowed fluticasone
Walter Reed Army Medical Center
2008 - NCT00895817 United States;
Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
Dallas VA Medical Center
2007 Phase 4 NCT01404832 United States;
Viaskin Milk 500 mcg
Children's Hospital of Philadelphia
2015 Phase 2 NCT02579876 United States;
Viscous/swallowed budesonide
University of North Carolina, Chapel Hill
2009 - NCT00961233 United States;
Vitamin D
Arkansas Children's Hospital Research Institute
2019 - NCT03615950 United States;
Vonoprazan
Second department of Internal Medicine, Shimane University Faculty of Medicine
2016 - JPRN-UMIN000021041 Japan;
Wheat
Mayo Clinic
2015 - NCT02434705 United States;
Xanthan gum
Walter Reed National Military Medical Center
2014 - NCT02125851 United States;
Xylose
Mayo Clinic
2014 - NCT02314455 United States;
Zofran - no intubation
Children's Hospital Medical Center, Cincinnati
2009 - NCT02038894 United States;
budesonide effervescent tablet for orodispersible use
Dr. Falk Pharma GmbH
2017 Phase 3 EUCTR2014-001485-99-DK Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-NL Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 Phase 3 EUCTR2014-001485-99-BE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2016 - EUCTR2014-001485-99-ES Spain;Switzerland;
2015 Phase 3 EUCTR2014-001485-99-GB Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001485-99-DE Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-001484-12-NL Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-ES Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-DE Belgium;Germany;Netherlands;Spain;Switzerland;
2015 Phase 3 EUCTR2014-001484-12-BE Belgium;Germany;Netherlands;Spain;Switzerland;
2012 Phase 2 EUCTR2009-016692-29-BE Belgium;Germany;Switzerland;